Lupus Nephritis

New England CEPAC

ICER plans to assess the comparative clinical effectiveness and value of voclosporin (Aurinia Pharmaceuticals, Inc.) and belimumab (BENLYSTA®, GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin is seeking an initial approval for the treatment of lupus nephritis, and belimumab is seeking a label expansion for the treatment of lupus nephritis; both are expecting FDA decisions in early 2021.

Date of review: March 2021

For questions, please contact Catherine Koola, Program Manager, at ckoola@icer-review.org.

Associated Meetings

March 26, 2021 9:30am-4pm ET

Virtual – details will be available closer to the meeting date

The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for lupus nephritis.


Key Dates

Associated Materials

08/10/2020 – 08/26/2020

08/31/2020

08/31/2020 – 09/21/2020
Public Comments

08/31/2020

09/29/2020
Revised Scoping Document

10/06/2020
Research Protocol

11/20/2020
Model Analysis Plan

01/22/2021
Draft Evidence Report

01/22/2021
Draft Voting Questions

01/22/2021 – 02/18/2021
Public Comments

03/12/2021
Revised Voting Questions

03/12/2021
Evidence Report

03/12/2021
Response to Public Comments

03/12/2021
Meeting Agenda

03/26/2021
Evidence Presentation

04/16/2021
Final Evidence Report and Meeting Summary

04/16/2021
Report-at-a-Glance

04/16/2021
Final Policy Recommendations